Literature DB >> 25753685

Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance.

Miyu Tajima1, Yusuke Shiozawa, Jiro Kagawa.   

Abstract

It is difficult to accurately predict treatment resistance in Kawasaki disease (KD). Patients considered to be low-risk cases often develop resistance to intravenous immunoglobulin (IVIG). We herein examined whether information from the clinical course of KD could improve the prediction accuracy of a previously reported risk score. We retrospectively reviewed the clinical records of 100 KD patients. The clinical characteristics and laboratory data were compared between IVIG-sensitive and IVIG-resistant patients and also between patients with and without coronary artery aneurysm (CAA). The total incidence of IVIG resistance and CAA development was 34 and 13 %, respectively. Multiple regression analysis identified the early appearance of principal symptoms (≤day 2 of the illness) as a risk factor for IVIG resistance (OR 2.88, 95 % CI 1.11-7.44, p = 0.0041), whereas delayed IVIG administration (≥day 6) (OR 2.23, 95 % CI 0.66-7.64, p = 0.018) and IVIG resistance (OR 9.05, 95 % CI 2.27-36.10, p = 0.015) were independent predictors for CAA development. The addition of the first appearance day of principal symptoms into a previously reported scoring system improved its prediction accuracy for IVIG resistance. KD patients who had presented with any principal symptoms within 2 days of fever onset were at a high risk for IVIG resistance regardless of previously reported risk score. A careful medical history-taking that is focused on the clinical course enables a better prediction of IVIG resistance.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25753685     DOI: 10.1007/s00246-015-1136-2

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  24 in total

Review 1.  Kawasaki disease: an update on diagnosis and treatment.

Authors:  Ho-Chang Kuo; Kuender D Yang; Wei-Chiao Chang; Luo-Ping Ger; Kai-Sheng Hsieh
Journal:  Pediatr Neonatol       Date:  2012-01-17       Impact factor: 2.083

2.  Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

Authors:  Kimiyasu Egami; Hiromi Muta; Masahiro Ishii; Kenji Suda; Yoko Sugahara; Motofumi Iemura; Toyojiro Matsuishi
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

3.  Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.

Authors:  Adriana H Tremoulet; Sonia Jain; Preeti Jaggi; Susan Jimenez-Fernandez; Joan M Pancheri; Xiaoying Sun; John T Kanegaye; John P Kovalchin; Beth F Printz; Octavio Ramilo; Jane C Burns
Journal:  Lancet       Date:  2014-02-24       Impact factor: 79.321

Review 4.  Kawasaki disease: late cardiovascular sequelae.

Authors:  Lori B Daniels; John B Gordon; Jane C Burns
Journal:  Curr Opin Cardiol       Date:  2012-11       Impact factor: 2.161

5.  Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.

Authors:  Satoshi Sato; Hisashi Kawashima; Yasuyo Kashiwagi; Akinori Hoshika
Journal:  Int J Rheum Dis       Date:  2013-04       Impact factor: 2.454

6.  Kawasaki disease as a systemic vasculitis in childhood.

Authors:  Kei Takahashi; Toshiaki Oharaseki; Yuki Yokouchi; Nobuyuki Hiruta; Shiro Naoe
Journal:  Ann Vasc Dis       Date:  2010-12-02

7.  Clinical characteristics of Kawasaki syndrome and the risk factors for coronary artery lesions in China.

Authors:  Yu Ruan; Bei Ye; Xiaodong Zhao
Journal:  Pediatr Infect Dis J       Date:  2013-10       Impact factor: 2.129

8.  Kawasaki syndrome and factors associated with coronary artery abnormalities in California.

Authors:  Laura S Callinan; Farzaneh Tabnak; Robert C Holman; Ryan A Maddox; Janice J Kim; Lawrence B Schonberger; Duc J Vugia; Ermias D Belay
Journal:  Pediatr Infect Dis J       Date:  2012-09       Impact factor: 2.129

9.  Recognising Kawasaki disease in UK primary care: a descriptive study using the Clinical Practice Research Datalink.

Authors:  Abigail Moore; Anthony Harnden; Richard Mayon-White
Journal:  Br J Gen Pract       Date:  2014-08       Impact factor: 5.386

Review 10.  Kawasaki Disease: A Clinician's Update.

Authors:  Nathan Jamieson; Davinder Singh-Grewal
Journal:  Int J Pediatr       Date:  2013-10-27
View more
  4 in total

Review 1.  Use of corticosteroids during acute phase of Kawasaki disease.

Authors:  Jeong Jin Yu
Journal:  World J Clin Pediatr       Date:  2015-11-08

2.  The prognostic role of abnormal liver function in IVIG unresponsiveness in Kawasaki disease: a meta-analysis.

Authors:  Ling Liu; Wei Yin; Ruigeng Wang; Dongming Sun; Xuelian He; Yan Ding
Journal:  Inflamm Res       Date:  2015-12-08       Impact factor: 4.575

3.  Risk Factors of Coronary Artery Abnormality in Children With Kawasaki Disease: A Systematic Review and Meta-Analysis.

Authors:  Fan Yan; Bo Pan; Huichao Sun; Jie Tian; Mi Li
Journal:  Front Pediatr       Date:  2019-09-26       Impact factor: 3.418

4.  Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.

Authors:  Xiaolan Zheng; Jinhui Li; Peng Yue; Lei Liu; Jiawen Li; Kaiyu Zhou; Yimin Hua; Yifei Li
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.